Champions Oncology (CSBR) Common Equity (2011 - 2026)

Champions Oncology's Common Equity history runs 16 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Common Equity fell 21.69% year-over-year to $4.3 million; the TTM figure through Jan 2026 stood at $4.3 million (down 21.69% YoY), while the FY2025 annual figure was $3.8 million, up 298.21% from the prior year.
• Common Equity was $4.3 million for Q1 2026 at Champions Oncology, up from $4.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $9.2 million in Q1 2022 to a low of -$2.1 million in Q1 2024.
• Historically, Common Equity has averaged $4.0 million across 5 years, with a median of $4.2 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Common Equity sank 141.05% in 2024, then jumped 1165.66% in 2025.
• A 5-year view of Common Equity shows it stood at $9.2 million in 2022, then tumbled by 98.99% to $93000.0 in 2023, then surged by 632.26% to $681000.0 in 2024, then soared by 521.29% to $4.2 million in 2025, then increased by 1.23% to $4.3 million in 2026.
• The last three Common Equity figures came in at $4.3 million (Q1 2026), $4.2 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.